76 related articles for article (PubMed ID: 15352041)
21. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.
Sakuma S; Kato Y; Nishigaki F; Sasakawa T; Magari K; Miyata S; Ohkubo Y; Goto T
Br J Pharmacol; 2000 Aug; 130(7):1655-63. PubMed ID: 10928971
[TBL] [Abstract][Full Text] [Related]
22. Targeted cellular immunotherapy with bifunctional antibodies.
Nelson H
Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
[TBL] [Abstract][Full Text] [Related]
23. The role of the T cell receptor, CD8, and LFA-1 in different stages of the cytolytic reaction mediated by alloreactive T lymphocyte clones.
Blanchard D; van Els C; Borst J; Carrel S; Boylston A; de Vries JE; Spits H
J Immunol; 1987 Apr; 138(8):2417-21. PubMed ID: 3104466
[TBL] [Abstract][Full Text] [Related]
24. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor.
Turatti F; Figini M; Alberti P; Willemsen RA; Canevari S; Mezzanzanica D
J Gene Med; 2005 Feb; 7(2):158-70. PubMed ID: 15538730
[TBL] [Abstract][Full Text] [Related]
25. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Haeryfar SM; Hoskin DW
J Leukoc Biol; 2001 Jan; 69(1):113-22. PubMed ID: 11200055
[TBL] [Abstract][Full Text] [Related]
27. Phosphatidylinositol 3-kinase inhibitors prevent mouse cytotoxic T-cell development in vitro.
Phu T; Haeryfar SM; Musgrave BL; Hoskin DW
J Leukoc Biol; 2001 May; 69(5):803-14. PubMed ID: 11358990
[TBL] [Abstract][Full Text] [Related]
28. CD2-CD48 interactions promote cytotoxic T lymphocyte induction and function: anti-CD2 and anti-CD48 antibodies impair cytokine synthesis, proliferation, target recognition/adhesion, and cytotoxicity.
Musgrave BL; Watson CL; Hoskin DW
J Interferon Cytokine Res; 2003 Feb; 23(2):67-81. PubMed ID: 12744772
[TBL] [Abstract][Full Text] [Related]
29. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
30. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
[TBL] [Abstract][Full Text] [Related]
31. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
Bolhuis RL; Roozemond RC; van de Griend RJ
J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
[TBL] [Abstract][Full Text] [Related]
32. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
Gravelle M; Ochi A
J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies.
van Seventer GA; Kuijpers KC; van Lier RA; de Groot ER; Aarden LA; Melief CJ
J Immunol; 1987 Oct; 139(8):2545-50. PubMed ID: 3498763
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody.
Yamada-Ohnishi Y; Azuma H; Urushibara N; Yamaguchi M; Fujihara M; Kobata T; Ikeda H
Stem Cells Dev; 2004 Jun; 13(3):315-22. PubMed ID: 15186727
[TBL] [Abstract][Full Text] [Related]
35. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
36. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion.
Saverino D; Tenca C; Zarcone D; Merlo A; Megiovanni AM; Valle MT; Manca F; Grossi CE; Ciccone E
J Immunol; 1999 Jan; 162(2):651-8. PubMed ID: 9916682
[TBL] [Abstract][Full Text] [Related]
37. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
38. Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2.
Mealey RH; Littke MH; Leib SR; Davis WC; McGuire TC
Vet Immunol Immunopathol; 2007 Jul; 118(1-2):121-8. PubMed ID: 17498813
[TBL] [Abstract][Full Text] [Related]
39. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
40. T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function.
Ferrini S; Cambiaggi A; Meazza R; Sforzini S; Marciano S; Mingari MC; Moretta L
Eur J Immunol; 1994 Oct; 24(10):2294-8. PubMed ID: 7925558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
